NCI-MATCH precision medicine clinical trial releases new findings

(ECOG-ACRIN Cancer Research Group) The released data is from three treatment arms, all single-arm phase 2 studies: the drug taselisib in patients with mutations in the PIK3CA gene (Arm I); the drug ado-trastuzumab emtansine (T-DM1) in patients with HER2-overexpressing tumors (Arm Q); and the drug AZD4547 in patients with mutations in the FGFR pathway (Arm W).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

In conclusion, STH have shown a chemo-preventive action on different colon cancer cell models.Graphical abstract
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, we confirm our initial findings from the proteomic screen and demonstrate that LASP1 can interact with both eIF4A and eIF4B. Importantly, the LASP1-eIF4A and LASP1-eIF4B interaction is shown to be CXCL12-dependent. In addition, the ability of CXCR4 to impact the phosphorylation of eIF4F regulatory proteins is provided. Taken together, we hypothesize that activation of CXCR4 can promote eIF4F complex formation and activity through LASP1 and cell signaling. As a result, the translation of oncogenic proteins is promoted thereby mediating an invasive and metastatic phenotype commonly associated with CXCR4. Mate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsCirculating formate is reduced in HER2+ breast cancer, non-small cell lung cancer and highly obese patients relative to healthy controls. Further studies are required to determine the relevance of these observations in other cancer types and diseases.
Source: Cancer and Metabolism - Category: Cancer & Oncology Source Type: research
Conclusion and Perspective With in-depth understandings of antibodies, linkers, and payloads, ADCs have also achieved great development. The linkage strategy and target diversity have already improved the delivery of the payloads to tumor tissues and reduced exposure to normal tissues. With the development of payloads, some novel potent payloads are used by ADCs, which allows researchers to exploit novel linkers to attach the antibody and payloads without disturbing their potency (Dragovich et al., 2018). Furthermore, some irrelevant antigen-target ADCs also may exert toxicity to tumor cells due to the vascular gap of tum...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 22 April 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Sangjoon Choi, Jinah Chu, Binnari Kim, Sang Yun Ha, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Heewon Han, Insuk Sohn, Kyoung-Mee KimIntratumoral heterogeneity of HER2 is common in gastric cancer (GC). However, a direct comparison between the results of HER2 immunohistochemistry (IHC) and next-generation sequencing (NGS)-based cancer panel tests has not been explored in GC. We aimed to determine optimal thresholds of HER2 overexpression to be detected by NGS with the data of 168 metastatic GC cases with known expression leve...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Conditions:   Metastatic Breast Carcinoma;   Locally Advanced Breast Cancer Intervention:   Drug: 68GaNOTA-Anti-HER2 VHH1 Sponsors:   Universitair Ziekenhuis Brussel;   Kom op tegen Kanker (Stand-up-to-Cancer), the Flemish cancer society;   Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit. Recruiting
Source: - Category: Research Source Type: clinical trials
Roche today announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
AbstractBackgroundWe recently reported the clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using surgical specimens; patients with homogeneously HER2 positive gastric cancer benefitted more from trastuzumab. However, the majority of patients are diagnosed by endoscopic biopsy, and surgical specimens are not available in these patients. The aim of this study is to verify clinical significance of HER2 heterogeneity on trastuzumab efficacy using biopsy specimens.MethodsEighty-seven patients, who received trastuzumab-based chemotherapy and whose endoscopic biopsy specimens were available for HE...
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
ConclusionsRT could offer significant survival benefit in luminal ‐A, luminal‐B, and especially HER2‐enriched young early‐stage breast cancer female patients. The results enabled clinicians to predict the benefits of RT and improve evidence‐based treatment for breast cancer patients.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | HER2 | Herceptin | Study